George Kumar, Senior Director at AstraZeneca, shared on LinkedIn:
“For the first time, Whole-genome sequencing reveals three follicular lymphoma subtypes with distinct cell of origin and patient outcomes
A new study in Cell Reports Medicine has identified three distinct subtypes of follicular lymphoma, each with different cells of origin, biology, and patient outcomes.
- Subtype C1 – BCL6-related, immune-active, and linked to favorable prognosis
- Subtype C2 – BCL2-IGH driven, enriched for chromatin modifier mutations
- Subtype C3 – high genomic instability, lacking hallmark translocations, associated with poorer prognosis
By integrating genomic and transcriptomic data, researchers demonstrated that FL is not a single disease entity, but a spectrum of molecularly distinct subtypes. This refined classification could guide personalized treatment strategies, improve risk stratification, and reshape how we manage patients with this common lymphoma.”
Title: Whole-genome sequencing reveals three follicular lymphoma subtypes with distinct cell of origin and patient outcomes
Authors: Weicheng Ren, Mingyu Yang, Xianhuo Wang, Man Nie, Yuhua Huang, Hui Wan, Dongbing Liu, Xiaobo Li, Xiaofei Ye, Bin Meng, Wenqi Jiang, Huiqiang Huang, Zhiming Li, Huilai Zhang, Kui Wu, Qiang Pan-Hammarström
More posts featuring George Kumar.